BC Week In Review | Nov 10, 2014
Clinical News

AMAP102: Phase IIa data

Top-line data from a double-blind Phase IIa trial in 116 patients with mild to moderate OA of the knee, either with or without hand OA, showed that AMAP102 missed the primary endpoint of reducing WOMAC...
BC Week In Review | Jun 10, 2013
Company News

Allenex, AnaMar deal

This month, Allenex will sell its 2.1% equity stake in AnaMar to AnaMar's main owner Koncentra Holding AB (Stockholm, Sweden) for SEK1.7 million ($256,581). Allenex became an owner in AnaMar in 1998. Allenex said it...
BC Week In Review | May 4, 2009
Clinical News

AMAP102: Phase I started

AnaMar began a double-blind, placebo-controlled, single and multiple ascending-dose, U.K. Phase I trial to evaluate oral AMAP102 in 48 healthy volunteers. AnaMar Medical AB , Göteborg, Sweden   Product: AMAP102   Business: Autoimmune   Molecular target:...
Items per page:
1 - 3 of 3